Schizophrenia Research
Volume 53, Issue 3 , Pages 229-238 , 15 January 2002

Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers

  • Ridha Joober

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, Que., H3A 1A1, Canada
    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • Guy A Rouleau

      Affiliations

    • Montreal General Hospital Research Institute, McGill University, Montreal, Que., Canada
    • ,
  • Samarthji Lal

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, Que., H3A 1A1, Canada
    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • Michael Dixon

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, Que., H3A 1A1, Canada
    • ,
  • Gillian O'Driscoll

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, Que., H3A 1A1, Canada
    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • Roberta Palmour

      Affiliations

    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • Lawrence Annable

      Affiliations

    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • David Bloom

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, Que., H3A 1A1, Canada
    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • ,
  • Pierre Lalonde

      Affiliations

    • L.H. Lafontaine Hospital, Université de Montréal, Montreal, Que., Canada
    • ,
  • Alain Labelle

      Affiliations

    • Royal Ottawa Hospital, University of Ottawa, Ottawa, Ont., Canada
    • ,
  • Chawki Benkelfat

      Affiliations

    • Department of Psychiatry, Allan Memorial Institute, McGill University, 1033 Pine Avenue West, Montreal, Que., H3A 1A1, Canada
    • Corresponding Author InformationCorresponding author. Address: Department of psychiatry, McGill University, 1033 Pine Avenue West, Montreal, Que., Canada, H3A 1A1. Tel.: +1-514-398-6732; fax: +1-514-398-4866

Received 21 October 2000 ,Accepted 16 May 2001.

References 

  1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA. 2000;97:8104–8109
  2. Annett M. The distribution of manual asymmetry. Br. J. Psychol. 1972;63:343–358
  3. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmeyer JP, et al. Effect of haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry. 1998;155:343
  4. Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit?. Am. J. Psychiatry. 1994;151:40–48
  5. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990;16:551–561
  6. Brown WA. Neuroleptic responsive versus resistant patients. In:  Shriqui CL,  Nasrallah HA editor. Contemporary Issues in the Treatment of Schizophrenia. 1st ed. Washington, DC: American Psychiatric Press; 1995;p. 479–496
  7. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry. 1995;152:1724–1729
  8. Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Res. 1992;42:129–144
  9. Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, et al. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch. Gen. Psychiatry. 1991;48:910–913
  10. Dunn LM. Peabody Picture Vocabulary Test-Revised. Minnesota: American Guidance Service; 1981;
  11. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol. Med. 1988;18:873–885
  12. Gittelman-Klein R, Klein DF. Premorbid asocial adjustment and prognosis in schizophrenia. J. Psychiatr. Res. 1969;7:35–53
  13. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, et al. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991;38:285–292
  14. Heaton, R.K., Chelune, G.J., Talley, J.L., Kay, G.G., Curtiss G., 1993. Wisconsin Card Sorting Test manual: Revised and expanded. Odessa, F.L., Psychological Assessment Resources.
  15. Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN. Computerized EEG: predictor of outcome in schizophrenia. J. Nerv. Ment. Dis. 1975;160:118–203
  16. Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psychiatry Neurosci. 1999;24:141–146
  17. van Kammen DP, Kelley ME, Yao JK, Gilbertson MW, Gurklis JA, Inosaka T, et al. Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res. 1996;64:47–58
  18. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  19. Karson CN, Bigelow LB, Kleinman JE, Weinberger DR, Wyatt RJ. Haloperidol-induced changes in blink rates correlate with changes in BPRS score. Br. J. Psychiatry. 1982;140:503–507
  20. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr. Bull. 1994;20:103–119
  21. Levin S, Yurgelun-Todd D, Craft S. Contributions of clinical neuropsychology to the study of schizophrenia. J. Abnorm. Psychol. 1989;98:341–356
  22. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol. Psychiatry. 1991;30:475–482
  23. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999;25:233–255
  24. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am. J. Psychiatry. 1997;154:475–482
  25. Meltzer HY, Lee M, Cola P. The evaluation of treatment resistance: biologic implications. J. Clin. Psychopharmacol. 1998;18:5s–11s
  26. Miller CD. Nam-Powers Scale. In:  Miller CD editors. Handbook of Research Design and Social Measurement. Newbury Park, CA: Sage Publications; 1991;p. 338–350
  27. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry. 1999;56:749–754
  28. Mohr P, Horacek L, Libiger J, Czobor P. Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophr. Res. 1998;30:91–99
  29. Moritz S, Krausz M, Gottwalz E, Lambert M, Perro C, Ganzer S, et al. Cognitive Dysfunction at Baseline Predicts Symptomatic 1-Year Outcome in First-Episode Schizophrenics. Psychopathology. 2000;33:48–51
  30. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984;10:160–203
  31. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry. 1994;51:849–859
  32. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch. Gen. Psychiatry. 1991;48:618–624
  33. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 1994;51:124–131
  34. Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, et al. Familial schizophrenia and treatment response. Am. J. Psychiatry. 1987;144:1271–1276
  35. Thurstone, I.L., Thurstone, T., 1949. Scientific Resource Associates, Chicago.
  36. Tsuang MT. Memory deficit and long-term outcome in schizophrenia: a preliminary study. Psychiatry Res. 1982;6:355–360
  37. Wechsler D. Wechsler Adult Intelligence Scale-Revised. Cleveland, Ohio: The Psychological Corporation; 1981;
  38. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol. Bull. 1988;24:112–117
  39. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, et al. Dopamine Blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry. 1989;146:905–908
  40. Zec RF. Neuropsychology of schizophrenia according to Kraepelin: disorders of volition and executive functioning. Eur. Arch. Psychiatry Clin. Neurosci. 1995;245:216–223
  41. Zipursky RB, Zhang-Wong J, Lambe EK, Bean G, Beiser M. MRI correlates of treatment response in first episode psychosis. Schizophr. Res. 1998;30:81–90

PII: S0920-9964(01)00279-1

Schizophrenia Research
Volume 53, Issue 3 , Pages 229-238 , 15 January 2002

Article Tools

* Image Usage & Resolution